![]() LOR (0.3 μg) or vehicle was injected IA into the damaged knee at 2, 3, or 4 weeks after OA induction. Methods: Knee instability/post-traumatic OA was surgically induced in rats by anterior cruciate ligament and partial medial meniscus transection (ACLT+pMMx). 2 A single IA LOR injection was evaluated in a rat model of knee instability to determine its protective and regenerative effects when injected at different timepoints after induction of post-traumatic OA. Lorecivivint (LOR), an intra-articular (IA), small-molecule CLK2/DYRK1A inhibitor that modulates the Wnt pathway, has been shown in animal studies to induce chondrogenesis, protect cartilage, and reduce inflammation and, thereby, improve joint health. 1 Current therapeutic options focus on alleviating symptoms and pain rather than disease modification. Posttraumatic OA accounts for approximately 12% of all OA cases. Objectives: Osteoarthritis (OA) is characterized by increased cartilage thinning, bone remodeling, and inflammation. 1 Formerly Biosplice Therapeutics, Inc., 2 Biosplice Therapeutics, Inc., San Diego, CA, United States. ![]() Tim Seo 1, Vishal Deshmukh 2, and Yusuf Yazici 2. PANLAR202 LORECIVIVINT, AN INTRA-ARTICULAR, SMALL-MOLECULE CLK2/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, PROVIDES CARTILAGE-PROTECTIVE EFFECTS IN AN ANIMAL MODEL OF POST-TRAUMATIC OSTEOARTHRITIS
0 Comments
Leave a Reply. |